GE Marquette Medical Systems has garnered two awards from research firm Frost & Sullivan for its use of market research: the Competitive Strategy Award and the Product Line Strategy Award.These awards are based on independent research and analysis of
GE Marquette Medical Systems has garnered two awards from research firm Frost & Sullivan for its use of market research: the Competitive Strategy Award and the Product Line Strategy Award.
These awards are based on independent research and analysis of companies in the healthcare industry. GE Marquette stood out as a sole-source provider of clinical information systems and devices for patient monitoring and cardiology, and the company has been recognized for forming Web-based alliances to keep it competitive, according to Mahpara Qureshi, Frost & Sullivan industry analyst.
GE Marquettes alliances with companies that produce technology complementary to its own products include Draeger, Critikon, NEC Medical Systems, CardioDynamics, Novametrix, Micro Medical, Data Critical, and Aspect Medical Systems. Wisconsin-based GE Marquettes products focus on diagnostic cardiology, patient monitoring, and clinical information systems.
Recently, GE Marquette signed a three-year contract with Consorta Catholic Resource Partners to provide patient monitoring systems and services to its 900 hospitals and clinics around the world.
Under this agreement, GE Marquette will be a preferred provider of patient monitoring solutions, including the Solar family of advanced vital sign monitoring systems, the Eagle model configured monitors, and the portable Dash monitor, which supports continuous patient monitoring during an ambulance or aircraft ride.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.